{"id":"NCT03393494","sponsor":"Padagis LLC","briefTitle":"Bioequivalence Study of Two Treatments in the Treatment of Acne Vulgaris on the Face","officialTitle":"Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Compare Perrigo's Adapalene/BP Gel to Galderma's Epiduo (Adapalene/BP) Gel, and Both Treatments to a Vehicle Control in the Treatment of Acne Vulgaris","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-12-13","primaryCompletion":"2018-09-30","completion":"2019-01-05","firstPosted":"2018-01-08","resultsPosted":"2021-01-05","lastUpdate":"2021-11-08"},"enrollment":825,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Acne Vulgaris"],"interventions":[{"type":"DRUG","name":"Adapalene and Benzoyl Peroxide Topical Gel","otherNames":[]},{"type":"DRUG","name":"Epiduo Topical Product","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"Perrigo active","type":"EXPERIMENTAL"},{"label":"Reference active","type":"ACTIVE_COMPARATOR"},{"label":"Perrigo placebo","type":"PLACEBO_COMPARATOR"}],"summary":"To compare the safety and efficacy of Perrigo's product to an FDA approved product for the treatment of Acne Vulgaris","primaryOutcome":{"measure":"Mean Percent Change From Baseline in the Papules and Pustules Lesion Count","timeFrame":"Day 1 to week 12","effectByArm":[{"arm":"Perrigo Active","deltaMin":68.18,"sd":28.96},{"arm":"Reference Active","deltaMin":63.56,"sd":31.57},{"arm":"Perrigo Placebo","deltaMin":50.72,"sd":35.12}],"pValues":[{"comp":"OG000 vs OG001","p":null}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":329},"commonTop":[]}}